HBeAg levels at week 24 predict response to 8 years of tenofovir in HBeAg-positive chronic hepatitis B patients
Alimentary Pharmacology and Therapeutics Oct 14, 2017
Wong D, et al. - This research was designed to assess the utility of measuring hepatitis B e antigen (HBeAg) levels for predicting HBeAg seroconversion and HBsAg loss under long-term tenofovir (TDF) therapy. Among HBeAg-positive chronic hepatitis B patients treated with long-term TDF, a decline in HBeAg levels by week 24 correlated with HBeAg seroconversion and HBsAg loss.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
